Practice parameter on the use of psychotropic medication in children and adolescents.
about
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disordersSafety and tolerability of desvenlafaxine in children and adolescents with major depressive disorder.Polypharmacy among children and adolescents with psychiatric disorders in a mental referral hospital in BotswanaUse of Psychotropic Medications among Youth in Treatment Foster Care.National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007Adverse effects of psychotropic medications in children: predictive factorsQuality of care for childhood attention-deficit/hyperactivity disorder in a managed care medicaid programAttention-deficit/hyperactivity disorder and telemental healthAntidepressant use in children and adolescents: Practice touch points to guide paediatricians.The treatment of severe child aggression (TOSCA) study: Design challenges.Changing patterns of alpha agonist medication use in children and adolescents 2009-2011Quality concerns in antipsychotic prescribing for youth: a review of treatment guidelines.Meditation or Medication? Mindfulness training versus medication in the treatment of childhood ADHD: a randomized controlled trial.Use of Mental Health Services by Children Ages Six to 11 With Emotional or Behavioral DifficultiesMother's country of birth and prescription of psychotropic medication in Swedish adolescents: a life course approachOnset of abnormal movements and cardiovascular symptoms after acute change in complex polypharmacy in a child with attention-deficit/hyperactivity disorder and mood symptoms.Trends in Atypical Antipsychotics Prescribed to Children Six Years of Age or Less on Medicaid in KentuckyAge of Onset, Duration, and Type of Medication Therapy for Attention-Deficit/Hyperactivity Disorder and Substance Use During Adolescence: A Multi-Cohort National Study.Six-month open-label follow-up of risperidone long-acting injection use in pediatric bipolar disorder.Psychotropic medication monitoring checklists: use and utility for children in residential care.Medical and nonmedical use of prescription stimulants: results from a national multicohort studySide effects from use of one or more psychiatric medications in a population-based sample of children and adolescents.Weight gain associated with taking psychotropic medication: an integrative review.Polypharmacy with antidepressants in children and adolescents.Background, clinical features and treatment of attention deficit hyperactivity disorder in children.Medication prescribed by Australian paediatricians: Psychotropics predominate.Does Patient Race/Ethnicity Influence Physician Decision-Making for Diagnosis and Treatment of Childhood Disruptive Behavior Problems?The Length of Child Anxiety Treatment in a Regional Health System.Psychotropic drug treatments for people with autism and other developmental disorders: a primer for practicing behavior analystsCanadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.Evidence Use in Mental Health Policy Making for Children in Foster Care.Attitudes and experience of youth and their parents with psychiatric medication and relationship to self-reported adherence.Long-term mental wellbeing of adolescents and young adults diagnosed with venous thromboembolism: results from a multistage mixed methods study.Providers' Behaviors and Beliefs on Prescribing Antipsychotic Medication to Children: A Qualitative Study.Assent as an ethical imperative in the treatment of ADHD.Health care quality measures for children and adolescents in Foster Care: feasibility testing in electronic records.PSYCHOTROPIC MEDICATIONS: AN UPDATE FOR SCHOOL PSYCHOLOGISTSCurrent state of evidence for medication treatment of preschool internalizing disorders
P2860
Q27009995-9935D832-DD39-4107-ADD2-BB22EA6602FBQ33632399-2756ACCF-43D7-41BA-A2C3-F9AA477D7E28Q33655284-B23CA6FE-155C-4DB3-8F47-DDD521977CD3Q33699936-E02308B0-6E9D-43BD-97A9-008E85E1BBC8Q34187891-3897D6B2-21C8-427A-B92D-AB4C80FAE04AQ34341232-FA39E591-59F0-401B-B20C-26018BAB7076Q34476693-087A7D22-D891-4A64-B1FD-16291CF08194Q34582405-EB8E1A69-2773-49FB-997C-490C7AD6DBBBQ35572613-4B7EB0D0-15B5-4AE1-9C90-F2D9E505B878Q35595839-F0623998-A76B-4336-B127-1772E64E288EQ35641630-7302D4B2-72E6-433A-ACBC-CE687AA66988Q35801186-E128C2B2-F842-459B-826D-8066F6CB2BDEQ36086314-FB00AA2F-0435-41FE-9506-AD94ABC0590CQ36303117-EB7865E7-059D-4981-8723-FB481FBCE11EQ36306919-EA1CF901-C6DE-44A3-B929-9AFC49337E46Q36493506-3B65731C-6645-4B4C-B472-6930671F0D57Q36730256-4F651825-16A6-42B0-8813-3F4B7B5631C2Q37040031-5B252B17-1BFF-465E-B913-520C4D7860F5Q37226984-38BA739D-9047-44B8-B9B8-065938353F62Q37567443-63B3E6E1-6A05-428F-B252-3ADAFEB645FBQ37594887-D03B0B57-CDDA-4332-816D-CBE5BD670D96Q37667578-D3FB0024-4511-42C0-9ABD-83C158A1CE37Q37865068-33297D87-EC89-4CFA-B4DC-398526173F15Q38063355-4795139E-FA38-4DD5-98B2-18D0A6DD473EQ38122410-9D0219A4-DC2F-4D02-9996-96F5029C1496Q38700848-C557BA02-7203-48F2-9314-7EF3F5750E3CQ40007874-20FBF5DE-732C-4F66-9060-51F5BD7F9055Q40017365-341D189B-1833-4EED-A846-C3F33B47BAE3Q41247017-DB18C2F3-2CC4-4384-85DD-4BB40D0F4EFCQ44142664-C0A98946-879E-43FF-AD3A-B858F0E681DBQ46028769-174BBA74-B3CF-4540-8700-8D82C2E53FCBQ47356859-4E9CB755-DDD5-482B-82A7-74228082EEDAQ47597239-324C5E6A-F55B-4671-B218-BD9FB3DBA2B0Q47761088-3B662027-7FA5-4DA7-BE0C-908503FA460FQ48024455-EA42E89E-1791-4E1C-A743-259F745132E4Q50285233-7712A243-936D-4258-8D4E-6A24B22A9047Q57804903-79E23564-30A6-4593-A511-26A7303458E1Q59075318-4D2C4316-2DB8-4050-80FE-C1FBB25B3C02
P2860
Practice parameter on the use of psychotropic medication in children and adolescents.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Practice parameter on the use of psychotropic medication in children and adolescents.
@en
Practice parameter on the use of psychotropic medication in children and adolescents.
@nl
type
label
Practice parameter on the use of psychotropic medication in children and adolescents.
@en
Practice parameter on the use of psychotropic medication in children and adolescents.
@nl
prefLabel
Practice parameter on the use of psychotropic medication in children and adolescents.
@en
Practice parameter on the use of psychotropic medication in children and adolescents.
@nl
P1476
Practice parameter on the use of psychotropic medication in children and adolescents.
@en
P2093
American Academy of Child and Adolescent Psychiatry
P304
P356
10.1097/CHI.0B013E3181AE0A08
P577
2009-09-01T00:00:00Z